Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging

Archives of Neurology

Volumn 62, Issue 12, 2005, Pages 1843-1847

  Massacesi, Luca ^a   Parigi, Alessandro ^a   Barilaro, Alessandro ^a   Repice, Anna Maria ^a   Pellicanò, Gianni ^a   Konze, Angela ^a   Siracusa, Gianfranco ^a   Taiuti, Rosanna ^a   Amaducci, Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; STOMACH PAIN; TOXOPLASMOSIS; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; BRAIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALITIS; FEMALE; GADOLINIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 28944446244     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.12.1843     Document Type: Article

References (18)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-1231.
2. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361:545-552.
3. Massacesi L. Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy. Clin Neurol Neurosurg. 2002;104:177-181.
4. Aarbakke J, Janka-Shaub B, Elion GB. Thiopurine biology and pharmacology. Trends Pharmacol Sci. 1997;18:3-7.
5. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991;338:1051-1055.
6. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry. 2001;70:574-579.
7. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis [letter]. Lancet. 1997;350:261.
8. Sudlow CLM, Counsell CE. Problems with UK government risk sharing scheme for assessing drugs for multiple sclerosis. BMJ. 2003;326:388-392.
9. Miller D, Grossmann R, Reingold S, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121:3-24.
10. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992;32:758-766.
11. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
12. Sormani MP, Molineaux PD, Gasperini C, et al. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. J Neurol Neurosurg Psychiatry. 1999;66:465-469.
13. Palace J, Newsom Davis J, Lecky B, et al. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50:1778-1783.
14. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsingremitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;61:251-258.
15. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon β-1b. Neurology. 2003;60:1849-1851.
16. Cavazzuti M, Merelli E, Tassone G, et al. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. Eur Neurol. 1997;38:284-290.
17. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611-619.
18. Waubant E, Goodkin DE, Sloan R, et al. A pilot study of MRI activity before and during interferon beta-1a therapy. Neurology. 1999;53:874-876.